Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia

Elias Jabbour, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Joseph D. Khoury, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa F. Khouri, Partow Kebriaei, Nitin Jain, Yesid Alvarado, Tapan M. Kadia, Shilpa Paul, Guillermo Garcia-Manero, Bouthaina S. Dabaja, Jan A. Burger, Courtney D. DiNardo, Naval A. Daver, Guillermo Montalban-BravoMusa Yilmaz, Maro Ohanian, Alessandra Ferrajoli, Jovitta Jacob, Meagan Rostykus, Rebecca Garris, Susan O’Brien, Hagop M. Kantarjian

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Keyphrases